Waters Corporation Appoints Pearl S. Huang to Board of Directors
December 10 2020 - 7:30AM
Business Wire
Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S.
Huang, President and CEO of Cygnal Therapeutics and venture partner
at Flagship Pioneering, has been appointed as a Director of Waters
Corporation, effective January 1, 2021.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201210005237/en/
Dr. Pearl S. Huang (Photo: Business
Wire)
“We are pleased to welcome Pearl to the Waters Board of
Directors,” said Dr. Flemming Ornskov, Chairman of the Board.
“Pearl is a distinguished executive with significant scientific
expertise in the discovery of biologics, small molecule and nucleic
acid-based therapies, as well as a proven track record in drug
discovery and the development of clinical trials. We look forward
to benefitting from Pearl’s perspectives and believe she will add
even greater value to Waters’ distinguished board of scientists and
business leaders.”
“Pearl brings a tremendous blend of scientific expertise, global
experience and an entrepreneurial spirit that is vital for Waters
as we look to grow our product and services footprint in both
pharmaceutical and clinical laboratories around the world,” said
Dr. Udit Batra, CEO and President, Waters Corporation. “We are very
fortunate to have Pearl join us and I look forward to working with
her on our journey ahead.”
“Waters holds an essential position as a pioneering innovator
whose products and services enable essential innovation in the
life, food and materials sciences,” said Dr. Huang. “I’m honored
and excited to work with the Board as well as Udit and the
leadership team to leverage my experience to help Waters pursue
opportunities for growth in the burgeoning pharma and biopharma
industries.”
Dr. Huang is President and CEO of Cygnal Therapeutics and
venture partner at Flagship Pioneering. She currently serves on the
boards of Cygnal Therapeutics and KSQ Therapeutics. She previously
held senior roles within the pharmaceutical industry, including
Senior Vice President and Global Head of Therapeutic Modalities at
Roche and Vice President and Global Head of Discovery Academic
Partnerships at GSK. Dr. Huang co-founded BeiGene in 2010 and
served as its Chief Scientific Officer. Before BeiGene, she led
teams in oncology discovery at both Merck and GSK. She has received
multiple awards and recognitions throughout her career. In 2020,
Dr. Huang was named to the PharmaVOICE 100, a list of the most
inspiring leaders in the life sciences, and was featured by
FiercePharma as one of the Fiercest Women in Life Sciences. She
received her undergraduate degree in life sciences from the
Massachusetts Institute of Technology and a Ph.D. in molecular
biology from Princeton University.
Additional Resources
- Waters Board of Directors
- Connect with Waters via Twitter, Facebook and LinkedIn
About Waters Corporation
Waters Corporation (NYSE:WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass
spectrometry, and thermal analysis innovations serving the life,
materials, and food sciences for more than 60 years. With more than
7,000 employees worldwide, Waters operates directly in 35
countries, including 15 manufacturing facilities, and with products
available in more than 100 countries.
Cautionary Statement
This release contains “forward-looking” statements regarding
future results and events, including statements regarding Dr.
Huang’s appointment. For this purpose, any statements that are not
statements of historical fact may be deemed forward-looking
statements. Without limiting the foregoing, the words “will,”
“feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”,
“suggests”, “appears”, “estimates”, “projects”, and similar
expressions, whether in the negative or affirmative, are intended
to identify forward-looking statements. Actual future results and
events may differ significantly from the results and events
discussed in the forward-looking statements within this release for
a variety of reasons, including the factors that are discussed in
the sections entitled “Forward-Looking Statements” and “Risk
Factors” of the Company’s annual report on Form 10-K for the year
ended December 31, 2019 as filed with the Securities and Exchange
Commission (“SEC”), as updated by the Company’s subsequent filings
with the SEC. The forward-looking statements included in this
release represent the Company’s estimates or views as of the date
of this release and should not be relied upon as representing the
Company’s estimates or views as of any date subsequent to the date
of this release. Except as required by law, the Company does not
assume any obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201210005237/en/
Kevin Kempskie Corporate Communications Waters Corporation
kevin_kempskie@waters.com 617-413-4333
Waters (NYSE:WAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2023 to Apr 2024